About

The ATDC Conference has been an integral part of education and case-based study of upcoming and new diabetes technology for over 30 years. This is an annual course designed to help healthcare providers caring for patients with diabetes, including but not limited to: endocrinologists/diabetes specialists, internists, pediatricians, family physicians, physician assistants, medical residents and fellows, advanced practice nurses, nurses, dietitians, social workers, and Certified Diabetes Care and Education Specialists (CDCES).

Attendees will have an opportunity to interact with leaders in the field and participate in detailed question and answer sessions with the experts. The 2026 ATDC conference will explore many facets of treating patients with both T1D and T2D. We will review the use of dual continuous glucose and ketone monitors in both T1D and T2D management especially in the inpatient setting. Continuing the theme of technology in diabetes management, there will be multiple sessions, across plenaries, on advances in hybrid closed-loop systems, and their emerging role managing T2D. Developing new algorithms as well as a look to the future with the role of Artificial Intelligence in diabetes care. The pitfalls of technology use go hand in hand with the increasing use of technology in medicine.

Attendees will have the opportunity to attend a peer-to-peer workshop where they discuss different cases and upcoming trials in the field of diabetes and obesity. We will also discuss the use of GLP1, GLP-1 + GIP analogs in the treatment, prevention, and reversal of complications of diabetes in the cardiovascular, gastrointestinal, and renal systems. We plan to discuss managing early diabetic kidney disease and “lipotoxicity”.

In addition to newer diabetes technology, there are also novel and alternate insulin delivery methods that are fast becoming a desirable option for many patients; however, the decision of when to consider these agents and the selection of appropriate patients can be challenging especially in the primary care setting. Obesity continues to be a global health epidemic and the emergence and rising incidence of obesity in T1D is becoming an increasing barrier in achieving glycemic targets. Traditional methods and novel agents to combat this epidemic will be discussed.

We will be discussing the role of dual glucose and ketone monitoring in managing diabetes during pregnancy, challenges in managing diabetes in the post-menopausal years, and different AID systems and setting lower targets during pregnancy associated with diabetes. There will be an update on the SURPASS CVOT trials, as well as a review on stem cell therapies in T1D. There will also be discussion regarding the future of cure for T1D especially using stem cells. The conference aims, using a multi-disciplinary approach, to empower providers to achieve better health beyond glycemic control in patients with diabetes. We will also host 4 keynotes across a wide range of topics over the 4-day conference.

There will be enough time for attendees to interact with industry-sponsored booths and device and pharmaceutical reps.

The conference is hosted by the Barbara Davis Center for Diabetes in conjunction with the University of Colorado Denver School of Medicine. It is supported by the Children’s Diabetes Foundation and both industry sponsors and grants.